David Bajor

David Bajor
About David Bajor

Dr. Bajor, under the mentorship of Dr. June and Dr. Vonderheide will generate engineered T-cells directed to kill prostate tumors. He plans to express PSMA (Prostate-Specific Membrane Antigen)-recognizing molecules on the surface of patient T-cells. PSMA is abnormally overexpressed on prostate cancer cells in high grade and hormone-refractory, metastatic disease. It is an established target in advanced prostate cancer, being exploited for the development of direct immunotherapy and imaging for this disease. If successful, the findings from this proposal will lead to the development of a cellular therapy for malignant hormone refractory prostate cancer that will destroy recurrent tumor while conferring persistent protection against newly arising PSMA-expressing tumors in patients.


The 2011 Emilio Bassini – PCF Young Investigator Award

David Bajor, MD

University of Pennsylvania


Robert Vonderheide, MD, DPhil and Carl June, MD